Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-08
2011-03-08
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S173000
Reexamination Certificate
active
07902188
ABSTRACT:
The present invention provides for compounds of formula (I), (Ia) and (Ib)Wherein:A is selected from C—X and N,B is selected from C—Y and N,R1is selected from H and (C1-C6)alkyl,R2is selected from H and (C1-C6)alkyl,X is selected from H, HO, C(O)NH2, NH2Y is selected from H, HO, NH2, Br, Cl and FZ is selected from H, HO, F, CONH2and CN;And pharmaceutically acceptable salts, solvates and prodrugs thereof;With the provisos that:for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1is H or (C1-C6)alkyl and R2is H or (C1-C6)alkyl at least one of X, Y and Z must be OH;for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1is H and R2is H, then X cannot be OH;these compounds are useful as a medicament.
REFERENCES:
patent: 2503059 (1950-04-01), Miescher et al.
patent: 2599000 (1952-06-01), Kerwin et al.
patent: 3381009 (1968-04-01), Palazzo et al.
patent: 3511836 (1970-05-01), Hess
patent: 3527761 (1970-09-01), Archibald et al.
patent: 3997666 (1976-12-01), Witte et al.
patent: 4026894 (1977-05-01), Winn et al.
patent: 4188390 (1980-02-01), Campbell
patent: 4252721 (1981-02-01), Silvestrini et al.
patent: 4315007 (1982-02-01), Manoury
patent: 4703063 (1987-10-01), Imai et al.
patent: 5077290 (1991-12-01), Fisher et al.
patent: 5258513 (1993-11-01), Van Keulen
patent: 5348956 (1994-09-01), Van Keulen
patent: 5576322 (1996-11-01), Takase et al.
patent: 5698560 (1997-12-01), Onoda et al.
patent: 6037346 (2000-03-01), Doherty et al.
patent: 6297382 (2001-10-01), Scott
patent: 2006/0052435 (2006-03-01), Van der Graaf et al.
patent: 0463756 (1992-01-01), None
patent: 0526004 (1992-07-01), None
patent: 0995750 (2000-04-01), None
patent: 0995751 (2000-04-01), None
patent: 1092718 (2001-04-01), None
patent: 1092719 (2001-04-01), None
patent: 851311 (1960-10-01), None
patent: 851911 (1960-10-01), None
patent: 2095353 (1997-10-01), None
patent: 1154907 (1996-09-01), None
patent: WO9111172 (1991-08-01), None
patent: WO 9218489 (1992-10-01), None
patent: WO9306104 (1993-04-01), None
patent: WO9307149 (1993-04-01), None
patent: WO9312095 (1993-06-01), None
patent: WO9400453 (1994-01-01), None
patent: WO9402518 (1994-02-01), None
patent: WO9405661 (1994-03-01), None
patent: WO9519978 (1995-07-01), None
patent: WO9621656 (1996-07-01), None
patent: WO9849166 (1998-11-01), None
patent: WO9855148 (1998-12-01), None
patent: WO9902159 (1999-01-01), None
patent: WO9924433 (1999-05-01), None
patent: WO9930697 (1999-06-01), None
patent: WO9932475 (1999-07-01), None
patent: WO9954333 (1999-10-01), None
patent: WO9954358 (1999-10-01), None
patent: WO9955679 (1999-11-01), None
patent: WO9964002 (1999-12-01), None
patent: WO9964008 (1999-12-01), None
patent: WO0002550 (2000-01-01), None
patent: WO0012075 (2000-03-01), None
patent: WO0024745 (2000-05-01), None
patent: WO0028993 (2000-05-01), None
patent: WO0033825 (2000-06-01), None
patent: WO0058361 (2000-10-01), None
patent: WO0074679 (2000-12-01), None
patent: WO0105401 (2001-01-01), None
patent: WO0113112 (2001-02-01), None
patent: WO0114879 (2001-03-01), None
patent: WO0127112 (2001-04-01), None
patent: WO0127113 (2001-04-01), None
Hoffman, Organic Chemistry: An Intermediate Text, Second Edition, 2004.
Berman, et al., “Femal Sexual Dysfunction: Incidence, Pahtophysiology, Evaluation, and Treatment Options”,Urology54, pp. 385-391 (1999).
Melman, et al., “The Epidemiology and Pathophysiology of Erectile Dysfunction”,The Journal of Urology161, pp. 5-11 (1999).
Gonzalez, et al., “[3H]7-OH-DPAT is Capable of Labeling Dopamine D2as well as D3Receptors”,European Journal of Pharmacology272, pp. R1-R3 (1995).
Ballard, et al., “Effects of Sildenafil on the Relaxation of Human Corpus Cavenosum Tissue In Vitro and on the Activities of cyclic Nucleotide Phosphodiesterase Isozymes”,The Journal of Urology159(6), pp. 2164-2171 (1998).
Rotella, et al., “N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction”,J. Med. Chem., 43, pp. 1257-1263 (2000).
Berge, et al., “Pharmaceutical Salts”,Journal of Pharmaceutical Sciences66(1), pp. 1-19 (1977).
Taub, et al., “Relationship between Contraction and Relaxation in Human and Rabbit Corpus Cavernosum”,Urology42(6), pp. 698-704 (1993).
Leiblum, “Definition and Classification of Female Secual Disorders”,International Journal of Impotence Research10(Suppl. 2), pp. S104-S106 (1998).
Goldstein, et al., “Vasculogenic Female Sexual Dysfunction: Vaginal Engorgement and Clitorial Erectile Insufficiency Syndromes”,International Journal of Impotence Research10(Suppl. 2), pp. S84-S90 (1998).
Park, et al., “Vasculogenic Female Sexual Dysfunction: The Hemodynamic Basis for Vaginal Engorgement Insufficiency and Clitoral Erectile Insufficiency”,International Journal of Impotence Research9, pp. 27-37 (1997).
Levin, “VIP, Vagina, Clitorial and Periurethral Glans—an Update on Human Female Genital Arousal”,Exp. Clin. Endocrinol. 98(2), pp. 61-69 (1991).
Lerner, et al., “A Review of Erectile Dysfunction: New Insights and More Questions”,The Journal of Urology149, pp. 1246-1255 (1993).
Feldman, et al., “Impotence and its Medical and Psychosocial Correlates: Resulst of the Massachusetts Male Aging Study”,The Journal of Urology151, pp. 54-61 (1994).
Naylor, “Endogennous Neurotransmitters Mediating Penile Erection”,British Journal of Urology81, pp. 424-431 (1998).
Carrier, et al., “Erectile Dysfunction”,Clinical Andrology23(4), pp. 773-782 (1994).
Perrone, et al, “Oxygen Derivatives of 3-(3-hydroxyphenyl)-N-n-propylpiperidine”, 35, pp. 3045-3049, (1992).
Stocker, et al., NIDA Notes, Research Findings, vol. 14, No. 6 (Mar. 2000).
Morissette, et al., Advanced Drug Delivery Reviews, 56, 275-300 (2004).
Brown, et al., Drug Discovery Today, vol. 12, pp. 757-766 (Sep. 2007).
Perrone, et al, “Oxygen Derivatives of 3-(3-hydroxyphenyl)-N-n-propylpiperidine”, J. Med. Chem., vol. 35, pp. 3045-3049, (1992).
Allerton Charlotte Moira Norfor
Baxter Andrew Douglas
Cook Andrew Simon
Hepworth David
Wong Stephen Kwok-Fung
Kispert Jennifer
Olson A. Dean
Pfizer Inc.
Saeed Kamal A
LandOfFree
Morpholine dopamine agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Morpholine dopamine agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Morpholine dopamine agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2639181